相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentin Garcia-Gutierrez et al.
BLOOD CANCER JOURNAL (2021)
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Rea et al.
BLOOD (2021)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Massimo Breccia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
FUTURE ONCOLOGY (2020)
Response and Resistance to BCR-ABL1-Targeted Therapies
Theodore P. Braun et al.
CANCER CELL (2020)
Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations
Luca Piscitani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy
Sonu Kumar Gupta et al.
ONCOLOGY REVIEWS (2020)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Paul W. Manley et al.
LEUKEMIA RESEARCH (2020)
Imatinib-induced interstitial pneumonitis - a literature review and case report
Olga Hilda Orasan et al.
JOURNAL OF MIND AND MEDICAL SCIENCES (2020)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dasatinib Dose Management for the Treatment of Chronic Myeloid Leukemia
Moshe Talpaz et al.
CANCER (2018)
Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier
Janice K. Laramy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Laura N. Eadie et al.
PLOS ONE (2018)
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Laura N. Eadie et al.
Oncotarget (2018)
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors
Tomer Meirson et al.
Oncotarget (2018)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Joseph Schoepfer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Jorge E. Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia
Emma H. McCafferty et al.
PEDIATRIC DRUGS (2018)
Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
De Lin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
Yihua E. Ye et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
Richat Abbas et al.
CLINICAL PHARMACOKINETICS (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways
Adnan A. Kadi et al.
RSC ADVANCES (2016)
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
Sara Redaelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
L. Lu et al.
LEUKEMIA (2015)
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
M. S. Zabriskie et al.
LEUKEMIA (2015)
Ponatinib: Accelerated Disapproval
Justin F. Gainor et al.
ONCOLOGIST (2015)
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects
Narayana I. Narasimhan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
被撤回的出版物: Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib (Retracted article. See vol. 34, pg. 163, 2019)
Poe-Hirr Hsyu et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells
Yue-Li Sun et al.
ONCOLOGY REPORTS (2014)
Resistant mutations in CML and Ph+ALL - role of ponatinib
Geoffrey D. Miller et al.
BIOLOGICS-TARGETS & THERAPY (2014)
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
Joseph M. Gozgit et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
Brian D. Furmanski et al.
CLINICAL CANCER RESEARCH (2013)
A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects
Richat Abbas et al.
CLINICAL DRUG INVESTIGATION (2013)
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
Laura N. Eadie et al.
LEUKEMIA & LYMPHOMA (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
Gunhild Keller-von Amsberg et al.
ONCOTARGETS AND THERAPY (2013)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
Mamduh Khateb et al.
BMC CANCER (2012)
Modulation of the ATPase and Transport Activities of Broad-Acting Multidrug Resistance Factor ABCC10 (MRP7)
Ekaterina V. Malofeeva et al.
CANCER RESEARCH (2012)
The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
Rupashree Sen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Quantitative- and Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension
Sandra C. dos Santos et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes
Tao Xue et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Jorge E. Cortes et al.
BLOOD (2012)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10-/- Mice
Elizabeth A. Hopper-Borge et al.
CANCER RESEARCH (2011)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2011)
Dasatinib A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Paul L. McCormack et al.
DRUGS (2011)
Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice
A. M. Prasad et al.
INDIAN JOURNAL OF PHARMACOLOGY (2011)
Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
Richat Abbas et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class
Eidarus Salah et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Daniel W. Sherbenou et al.
BLOOD (2010)
Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
Noelia Nebot et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Metabolism considerations for kinase inhibitors in cancer treatment
Derek R. Duckett et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
Onder Tonyali et al.
MEDICAL ONCOLOGY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib
Marius Dohse et al.
DRUG METABOLISM AND DISPOSITION (2010)
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C. Hegedus et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
Ophelia Q. P. Yin et al.
CLINICAL THERAPEUTICS (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
Timothy Eley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Dasatinib - In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
Susan J. Keam
BIODRUGS (2008)
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Artur Gontarewicz et al.
BLOOD (2008)
Interaction of imatinib with human organic ion carriers
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
Devendra K. Hiwase et al.
CLINICAL CANCER RESEARCH (2008)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
Metabolism and disposition of dasatinib after oral administration to humans
Lisa J. Christopher et al.
DRUG METABOLISM AND DISPOSITION (2008)
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2
S. Shukla et al.
LEUKEMIA (2008)
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
C. Brendel et al.
LEUKEMIA (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome
JH Beumer et al.
PHARMACOTHERAPY (2006)
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy
K Wyman et al.
CANCER (2006)
Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers
M Marull et al.
JOURNAL OF MASS SPECTROMETRY (2006)
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines
Hans Prenen et al.
PHARMACOLOGY (2006)
Metabolism and disposition of imatinib mesylate in healthy volunteers
HP Gschwind et al.
DRUG METABOLISM AND DISPOSITION (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance - Focus on tamoxifen, paclitaxel and imatinib metabolism
B Rochat
CLINICAL PHARMACOKINETICS (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
B Arora et al.
ANNALS OF ONCOLOGY (2004)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
H Burger et al.
BLOOD (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger et al.
PHARMACOLOGICAL REVIEWS (2003)
Molecular mechanisms of transformation by the BCR-ABL oncogene
M Sattler et al.
SEMINARS IN HEMATOLOGY (2003)
Pdgfr-α mediates testis cord organization and fetal Leydig cell development in the XY gonad
J Brennan et al.
GENES & DEVELOPMENT (2003)
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis
K Ohyashiki et al.
LEUKEMIA (2002)
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
T Hegedüs et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
P Vigneri et al.
NATURE MEDICINE (2001)
Stem cell factor and insulin-like growth factor-I stimulate luteinizing hormone-independent differentiation of rat ovarian theca cells
CTF Huang et al.
BIOLOGY OF REPRODUCTION (2001)
分享论文
